FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991381877> ?p ?o ?g. }

• W1991381877 endingPage "1777" @default.
• W1991381877 startingPage "1771" @default.
• W1991381877 abstract "Patients with recurrent/metastatic endometrial cancer that progresses after chemotherapy have limited treatment options and poor outcomes. Preclinical data suggest the oral mammalian target of rapamycin inhibitor everolimus may provide clinical benefit in these patients.In this multicenter, open-label, phase 2 study, patients with advanced or metastatic endometrial cancer refractory to one or two previous chemotherapy regimens received everolimus 10 mg per day until progression or unacceptable toxicity. Primary end point was the non-progressive disease rate at 3 months. Secondary end points included duration of response, progression-free, and overall survival (OS), and safety.Forty-four patients were enrolled (median age, 65 years); 66% received one previous chemotherapy regimen. The 3-month non-progressive disease rate was 36% (95% confidence interval 22-52%), including two patients (5%) with partial response (PR). At 6 months, two additional patients experienced PR. Median duration of response was 3.1 months. Median progression-free and OS were 2.8 months and 8.1 months, respectively. The most common adverse events were anaemia (100%), fatigue (93%), hypercholesterolaemia (81%), and lymphopenia (81%).Everolimus demonstrated efficacy and acceptable tolerability in patients with chemotherapy-refractory advanced or metastatic endometrial cancer. These results support the further development of phosphatidylinositol 3-kinase-targeted therapies in endometrial cancer." @default.
• W1991381877 created "2016-06-24" @default.
• W1991381877 creator A5004452040 @default.
• W1991381877 creator A5039713572 @default.
• W1991381877 creator A5042166901 @default.
• W1991381877 creator A5042461515 @default.
• W1991381877 creator A5070962149 @default.
• W1991381877 creator A5073063132 @default.
• W1991381877 creator A5073713547 @default.
• W1991381877 creator A5079609936 @default.
• W1991381877 creator A5086083902 @default.
• W1991381877 creator A5091368872 @default.
• W1991381877 creator A5091655083 @default.
• W1991381877 date "2013-04-23" @default.
• W1991381877 modified "2023-10-09" @default.
• W1991381877 title "Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO" @default.
• W1991381877 cites W1540317073 @default.
• W1991381877 cites W1885232396 @default.
• W1991381877 cites W1975352300 @default.
• W1991381877 cites W1981989535 @default.
• W1991381877 cites W1988609792 @default.
• W1991381877 cites W2024029450 @default.
• W1991381877 cites W2024675894 @default.
• W1991381877 cites W2029409133 @default.
• W1991381877 cites W2039156383 @default.
• W1991381877 cites W2047271282 @default.
• W1991381877 cites W2054371201 @default.
• W1991381877 cites W2082568558 @default.
• W1991381877 cites W2095252208 @default.
• W1991381877 cites W2101549875 @default.
• W1991381877 cites W2112169652 @default.
• W1991381877 cites W2113458582 @default.
• W1991381877 cites W2115686439 @default.
• W1991381877 cites W2115940673 @default.
• W1991381877 cites W2119607431 @default.
• W1991381877 cites W2138129102 @default.
• W1991381877 cites W2139248078 @default.
• W1991381877 cites W2142188072 @default.
• W1991381877 cites W2148407509 @default.
• W1991381877 cites W2154893943 @default.
• W1991381877 cites W2158734599 @default.
• W1991381877 cites W2165901246 @default.
• W1991381877 cites W2165992619 @default.
• W1991381877 cites W2529670685 @default.
• W1991381877 cites W2566303757 @default.
• W1991381877 cites W2589405267 @default.
• W1991381877 cites W3025735868 @default.
• W1991381877 doi "https://doi.org/10.1038/bjc.2013.183" @default.
• W1991381877 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3658508" @default.
• W1991381877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23612453" @default.
• W1991381877 hasPublicationYear "2013" @default.
• W1991381877 type Work @default.
• W1991381877 sameAs 1991381877 @default.
• W1991381877 citedByCount "90" @default.
• W1991381877 countsByYear W19913818772012 @default.
• W1991381877 countsByYear W19913818772013 @default.
• W1991381877 countsByYear W19913818772014 @default.
• W1991381877 countsByYear W19913818772015 @default.
• W1991381877 countsByYear W19913818772016 @default.
• W1991381877 countsByYear W19913818772017 @default.
• W1991381877 countsByYear W19913818772018 @default.
• W1991381877 countsByYear W19913818772019 @default.
• W1991381877 countsByYear W19913818772020 @default.
• W1991381877 countsByYear W19913818772021 @default.
• W1991381877 countsByYear W19913818772022 @default.
• W1991381877 countsByYear W19913818772023 @default.
• W1991381877 crossrefType "journal-article" @default.
• W1991381877 hasAuthorship W1991381877A5004452040 @default.
• W1991381877 hasAuthorship W1991381877A5039713572 @default.
• W1991381877 hasAuthorship W1991381877A5042166901 @default.
• W1991381877 hasAuthorship W1991381877A5042461515 @default.
• W1991381877 hasAuthorship W1991381877A5070962149 @default.
• W1991381877 hasAuthorship W1991381877A5073063132 @default.
• W1991381877 hasAuthorship W1991381877A5073713547 @default.
• W1991381877 hasAuthorship W1991381877A5079609936 @default.
• W1991381877 hasAuthorship W1991381877A5086083902 @default.
• W1991381877 hasAuthorship W1991381877A5091368872 @default.
• W1991381877 hasAuthorship W1991381877A5091655083 @default.
• W1991381877 hasBestOaLocation W19913818772 @default.
• W1991381877 hasConcept C121608353 @default.
• W1991381877 hasConcept C126322002 @default.
• W1991381877 hasConcept C141071460 @default.
• W1991381877 hasConcept C143998085 @default.
• W1991381877 hasConcept C197934379 @default.
• W1991381877 hasConcept C203092338 @default.
• W1991381877 hasConcept C2776694085 @default.
• W1991381877 hasConcept C2777088508 @default.
• W1991381877 hasConcept C2778336483 @default.
• W1991381877 hasConcept C2778375690 @default.
• W1991381877 hasConcept C2778822529 @default.
• W1991381877 hasConcept C2779699572 @default.
• W1991381877 hasConcept C2779984678 @default.
• W1991381877 hasConcept C2780739268 @default.
• W1991381877 hasConcept C2781413609 @default.
• W1991381877 hasConcept C31760486 @default.
• W1991381877 hasConcept C535046627 @default.
• W1991381877 hasConcept C71924100 @default.
• W1991381877 hasConceptScore W1991381877C121608353 @default.

• next